Payment overview · 2025
General Payments
$435.41
19 reported records · 11 companies
Healthcare provider profile · identity verified
Patrick Romeus, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1669464335
Verified facts
What the public records show
CMS Open Payments records show Patrick Romeus, MD received $435.41 in general payments during 2025 across 19 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.97 | 18.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.89 | 14.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.15 | 13.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.31 | 11.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.22 | 10.8% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.21 | 6.7% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $27.80 | 6.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.23 | 4.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.44 | 4.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.10 | 4.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.09 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.41 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.97 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.89 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.22 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1179 | 343 |
| Atorvastatin Calcium | Atorvastatin Calcium | 947 | 310 |
| Losartan Potassium | Losartan Potassium | 768 | 247 |
| Metformin Hcl | Metformin Hcl | 598 | 182 |
| Nifedipine Er | Nifedipine | 388 | 119 |
| Gabapentin | Gabapentin | 361 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 123 |
| Glipizide | Glipizide | 305 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 284 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 72 |
| Lisinopril | Lisinopril | 267 | 80 |
| Omeprazole | Omeprazole | 261 | 104 |
| Hydralazine Hcl | Hydralazine Hcl | 259 | 75 |
| Simvastatin | Simvastatin | 251 | 66 |
| Eliquis | Apixaban | 229 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 46 |
| Carvedilol | Carvedilol | 207 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 94 |
| Ibuprofen | Ibuprofen | 184 | 102 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 87 |
| Donepezil Hcl | Donepezil Hcl | 158 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 37 |
| Clonidine Hcl | Clonidine Hcl | 143 | 46 |
| Furosemide | Furosemide | 141 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 134 | 51 |
| Levetiracetam | Levetiracetam | 128 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 48 |
| Glimepiride | Glimepiride | 113 | 37 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 108 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 54 |
| Meloxicam | Meloxicam | 104 | 54 |
| Azithromycin | Azithromycin | 103 | 84 |
| Baclofen | Baclofen | 97 | 19 |
| Alendronate Sodium | Alendronate Sodium | 96 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Latanoprost | Latanoprost | 90 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 87 | 22 |
| Famotidine | Famotidine | 85 | 40 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 83 | 13 |
| Farxiga | Dapagliflozin Propanediol | 82 | 26 |
| Januvia | Sitagliptin Phosphate | 81 | 26 |
| Atenolol | Atenolol | 79 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 31 |
| Novolog Flexpen | Insulin Aspart | 69 | 15 |
| Naproxen | Naproxen | 68 | 35 |
| Finasteride | Finasteride | 67 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 24 |
| Xarelto | Rivaroxaban | 66 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 54 |
| Lactulose | Lactulose | 62 | 18 |
| Meclizine Hcl | Meclizine Hcl | 61 | 33 |
| Ozempic | Semaglutide | 60 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 57 | 11 |
| Allopurinol | Allopurinol | 56 | 13 |
| Jardiance | Empagliflozin | 55 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 45 |
| Mirtazapine | Mirtazapine | 53 | 24 |
| Ketoconazole | Ketoconazole | 52 | 33 |
| Aptiom | Eslicarbazepine Acetate | 50 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 50 | 14 |
| Montelukast Sodium | Montelukast Sodium | 49 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 13 |
| Entresto | Sacubitril/Valsartan | 48 | 14 |
| Megestrol Acetate | Megestrol Acetate | 47 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 13 |
| Memantine Hcl | Memantine Hcl | 45 | 14 |
| Glipizide Er | Glipizide | 44 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 18 |
| Risperidone | Risperidone | 42 | 11 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 42 | 32 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 28 |
| Invokana | Canagliflozin | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 26 |
| Scopolamine | Scopolamine | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 13 |
| Spironolactone | Spironolactone | 33 | 11 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 16 |
| Enulose | Lactulose | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | 13 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | 13 |
| Dorzolamide Hcl | Dorzolamide Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 15 |
| Fluconazole | Fluconazole | 26 | 17 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | 12 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Lumigan | Bimatoprost | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Risperidone Er | Risperidone Microspheres | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Cephalexin | Cephalexin | 14 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.41 · 19 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Dexcom G6 Transmitter, FARXIGA, Kerendia, LUPKYNIS, MINIMED 780G, MOUNJARO, Ozempic, REPATHA, REXULTI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error